PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors

Launched by AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY · Nov 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging tracer called 68Ga-FAPI-JNU, which is being tested in patients with cancer, specifically those with solid tumors. The main goal of the study is to understand how this tracer spreads throughout the body, particularly in cancerous tissues and normal tissues. By using this new tracer, researchers hope to improve the way doctors can see and understand tumors during imaging tests.

To participate in this trial, individuals must be between 18 and 80 years old and have a clinically diagnosed malignant tumor, confirmed by a biopsy or imaging tests like CT or MRI. Participants should be able to follow the study guidelines and must not have certain health conditions that could affect their ability to undergo a PET/CT scan. If eligible, participants can expect to undergo imaging tests that involve this new tracer, helping researchers gather important information that could lead to better cancer diagnosis and treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;
• • 2. Age 18-85 years old, male or female;
• • 3. Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;
• • 4. ECOG score is 0-3 points;
• Exclusion Criteria:
• • 1. Patients with a history or allergic constitution to any component of the developer, including alcohol;
• • 2. pregnant or lactating women;
• • 3. Patients with mental illness or related history;
• • 4. Patients who cannot or cannot undergo a PET/CT scan;